Given that there are no approved agents that directly inhibit glucose metabolism, indirectly targeting glycolysis with signal transduction inhibitors in combination with glutaminase inhibition represents an attractive therapeutic strategy for RCC. This evidence concerns the gene GLS and renal cell carcinoma.